DarioHealth Reports Second Quarter 2024 Financial and Operating Results
DarioHealth reported Q2 2024 financial results with revenue of $6.26 million, up 8.6% from Q1 2024 and 1.7% year-over-year. The core B2B2C revenue channel saw 315% year-over-year growth to $5.5 million. The company is making progress on transforming its pharma channel to a recurring revenue model. DarioHealth expects to reduce operating expenses by 40% by Q1 2025 and reach cashflow breakeven by the end of 2025. The company ended Q2 with $22.9 million in cash. DarioHealth is seeing increased adoption of its GLP-1 product across clients seeking metabolic solutions. The company anticipates significant reductions in operating losses over the next three quarters driven by revenue growth and cost-cutting measures.
DarioHealth ha riportato i risultati finanziari del secondo trimestre del 2024, con un fatturato di 6,26 milioni di dollari, in aumento dell'8,6% rispetto al primo trimestre del 2024 e dell'1,7% su base annua. Il canale principale di fatturato B2B2C ha visto una crescita del 315% su base annua, raggiungendo 5,5 milioni di dollari. L'azienda sta facendo progressi nella trasformazione del suo canale farmaceutico in un modello di fatturato ricorrente. DarioHealth prevede di ridurre le spese operative del 40% entro il primo trimestre del 2025 e di raggiungere il pareggio di flusso di cassa entro la fine del 2025. L'azienda ha concluso il secondo trimestre con 22,9 milioni di dollari in contanti. DarioHealth sta osservando un aumento nell'adozione del suo prodotto GLP-1 da parte dei clienti che cercano soluzioni metaboliche. L'azienda prevede significative riduzioni delle perdite operative nei prossimi tre trimestri grazie alla crescita dei ricavi e alle misure di riduzione dei costi.
DarioHealth reportó los resultados financieros del segundo trimestre de 2024, con ingresos de 6.26 millones de dólares, un aumento del 8.6% con respecto al primer trimestre de 2024 y del 1.7% interanual. El canal de ingresos B2B2C central experimentó un crecimiento del 315% interanual, alcanzando 5.5 millones de dólares. La compañía está avanzando en la transformación de su canal farmacéutico hacia un modelo de ingresos recurrentes. DarioHealth espera reducir los gastos operativos en un 40% para el primer trimestre de 2025 y alcanzar el equilibrio de flujo de caja para finales de 2025. La empresa cerró el segundo trimestre con 22.9 millones de dólares en efectivo. DarioHealth está viendo una mayor adopción de su producto GLP-1 entre clientes que buscan soluciones metabólicas. La compañía anticipa reducciones significativas en las pérdidas operativas durante los próximos tres trimestres impulsadas por el crecimiento de los ingresos y medidas de reducción de costos.
DarioHealth는 2024년 2분기 재무 결과를 보고했으며, 수익은 626만 달러로 2024년 1분기 대비 8.6% 증가하고 전년 대비 1.7% 증가했습니다. 핵심 B2B2C 수익 채널은 전년 대비 315% 성장하여 550만 달러에 달했습니다. 이 회사는 제약 채널을 반복 수익 모델로 전환하는 데 진전을 보고 있습니다. DarioHealth는 2025년 1분기까지 운영비를 40% 줄일 것으로 예상하며, 2025년 말까지 현금 흐름 손익 분기를 달성할 예정입니다. 이 회사는 2분기를 2,290만 달러의 현금으로 마쳤습니다. DarioHealth는 대사 솔루션을 찾는 고객들 사이에서 GLP-1 제품의 채택이 증가하고 있음을 보고 있습니다. 이 회사는 수익 성장과 비용 절감 조치로 인해 향후 3분기 동안 운영 손실이 크게 줄어들 것으로 예상합니다.
DarioHealth a annoncé les résultats financiers du deuxième trimestre 2024, avec un chiffre d'affaires de 6,26 millions de dollars, en hausse de 8,6 % par rapport au premier trimestre 2024 et de 1,7 % par rapport à l'année précédente. Le canal de revenus B2B2C a connu une croissance de 315 % par rapport à l'année précédente, atteignant 5,5 millions de dollars. L'entreprise progresse dans la transformation de son canal pharmaceutique en un modèle de revenus récurrents. DarioHealth prévoit de réduire ses coûts d'exploitation de 40 % d'ici le premier trimestre 2025 et d'atteindre l'équilibre de la trésorerie d'ici la fin 2025. L'entreprise a terminé le deuxième trimestre avec 22,9 millions de dollars en cash. DarioHealth observe une adoption croissante de son produit GLP-1 parmi les clients recherchant des solutions métaboliques. L'entreprise s'attend à des réductions significatives des pertes d'exploitation au cours des trois prochains trimestres, grâce à la croissance des revenus et aux mesures de réduction des coûts.
DarioHealth hat die finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlicht, mit Einnahmen von 6,26 Millionen Dollar, was einem Anstieg von 8,6 % im Vergleich zum ersten Quartal 2024 und 1,7 % im Vergleich zum Vorjahr entspricht. Der zentrale B2B2C-Umsatzkanal verzeichnete ein Wachstum von 315 % im Vergleich zum Vorjahr und erreichte 5,5 Millionen Dollar. Das Unternehmen macht Fortschritte bei der Umwandlung seines Pharmakanals in ein wiederkehrendes Einnahmemodell. DarioHealth rechnet damit, die Betriebskosten bis zum ersten Quartal 2025 um 40 % zu senken und bis Ende 2025 den Cashflow-Punkt zu erreichen. Das Unternehmen schloss das zweite Quartal mit 22,9 Millionen Dollar in bar ab. DarioHealth sieht eine zunehmende Akzeptanz seines GLP-1-Produkts bei Kunden, die nach metabolischen Lösungen suchen. Das Unternehmen erwartet signifikante Reduzierungen der Betriebskosten in den nächsten drei Quartalen, bedingt durch Umsatzwachstum und Kostensenkungsmaßnahmen.
- Q2 revenue increased 8.6% quarter-over-quarter to $6.26 million
- Core B2B2C revenue grew 315% year-over-year to $5.5 million
- Expects to reduce operating expenses by 40% by Q1 2025
- Anticipates reaching cashflow breakeven by end of 2025
- Ended Q2 with $22.9 million in cash
- Seeing increased adoption of GLP-1 product across clients
- Granted a one-time price concession of $1.1 million to a strategic partner
- Potential near-term reduction in pharma channel revenues during business model transition
- Operating loss increased 15.5% year-over-year to $16.2 million in Q2
Insights
DarioHealth's Q2 2024 results show mixed signals. While revenue increased 8.6% sequentially to
The company's focus on cost-cutting measures and expected gross margin improvement to
DarioHealth's strategic pivot towards a B2B2C model and integration of Twill's platform shows promise in the digital health space. The company's focus on GLP-1 product adoption aligns well with current market trends, with 9 clients already implementing and more expected in 2024. This could be a significant growth driver.
The emphasis on AI capabilities and data monetization presents intriguing opportunities, particularly in drug discovery and personalized healthcare. However, the transition from milestone-based to recurring revenue in the pharma channel may cause short-term revenue volatility. The cross-selling success of the Twill platform to existing Dario clients demonstrates the potential for synergies, but execution will be key to realizing these benefits.
DarioHealth's Q2 results reflect the ongoing transformation of its business model. The
The company's focus on the GLP-1 market is timely, given the surge in demand for weight loss solutions. The integration of Twill's platform and cross-selling efforts could drive future growth. However, investors should closely monitor the pharma channel transition and its impact on near-term revenues. The projected
- Q2 revenue of
$6.26 million 8.6% over Q1 2024, and an increase of1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues - Q2 commercial and consumer revenues totaled
$7.34 million $3.57 million 105% increase - Core B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled
$5.5 million 315% year over year and60% sequentially from the first quarter of 2024 - Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring, and more stable revenue-based business model in our pharma channel, which is currently milestone based.
- Strong business momentum on cross selling of Twill offering to Dario clients with at least 10 initial clients
- Executed on Dario-Twill synergies that expect to reduce operating expenses by approximately
40% by Q1 2025 compared to Q1 2024, aiding in an expected reduction in operating losses of at least70% by Q1 2025 - Saw increased GLP-1 product adoption across new and existing clients seeking our metabolic solutions, with 9 clients implementing already and several more expected in 2024.
- Company expects to reach cashflow breakeven by the end of 2025
- Ended Q2 2024 with cash equivalents of
$22.9 million - Company to host investor conference call and webcast at 8:30 a.m. ET today
Q2 2024 and Recent Highlights
In the second quarter, we drove significant growth in our core business-to-business-to-consumer (B2B2C) channel. Our B2B2C channel grew
We are continuing the momentum of scaling of our business and realizing the benefits of the strategic decisions we have made over the past few quarters. Our growing confidence in our ability to meet our target of cash flow breakeven by the end of 2025 is supported by recent progress in our core high margin B2B2C channel that reached
"Looking ahead, we anticipate a significant reduction in operating losses over the next three quarters driven by continued revenue growth and aggressive cost-cutting measures implemented post-Twill merger. These cost reduction initiatives, which commenced in early May 2024 and were completed in early August 2024, are expected to yield a
"Our core B2B2C revenue saw an increase in the second quarter as we saw the significant impact of new customer launches, customer expansions, and the transformative impact of the Twill acquisition," stated Steven Nelson, Dario's Chief Commercial Officer. "We continue to see meaningful traction with our GLP-1 product among new and existing contracts, with 9 clients already implementing the product and several others in the pipeline. We see an increasing opportunity for revenue growth with the GLP-1 product as more and more clients have expressed interest in this product each quarter. Aetna continues to add customers to its existing Mind Companion platform, a trend we expect to continue. We've signed agreements to expand with a health plan customer and other off-cycle employers, which are anticipated to launch this year.
Our commercial pharma channel, traditionally reliant on milestone-based revenue, presents a significant growth opportunity. The industry's shift towards direct-to-consumer models aligns perfectly with our expanded capabilities following the acquisition of Twill. We are confident that our Dario-Twill consumer hub platform, coupled with our enhanced offerings, positions us as a premier partner for pharma companies seeking to engage patients effectively. We are actively collaborating with existing and potential pharma clients to accelerate this transformation and maximize the value of our new, recurring, and more stable revenue-based business model. To facilitate this strategic transition, we have granted a one-time price concession of
We see a growing opportunity to expand on our foundational artificial intelligence (AI) capabilities given the data and tools that have had for years and are now of growing importance to our business model. We believe that the integration of generative AI and microservices is set to revolutionize drug discovery, consumer engagement, and personalization, with proprietary data sets poised for internal and external monetization, and we have a market leading capability to capitalize on this movement. With our strong cash position, we believe that we are well-equipped to execute our strategy and solidify Dario's leadership in the digital health space," concluded Mr. Nelson.
Additional Q2 2024 and Recent Highlights
- Signed multiple new customer contracts and obtained commitments from some Dario clients to adopt the Twill platform beginning in January 2025, because of cross selling efforts.
- Announced a strategic management restructuring with the appointment of Steven Nelson as Dario's inaugural Chief Commercial Officer.
- Announced two new studies presented at the 84th Annual American Diabetes Association (ADA) Scientific Sessions in
Orlando , demonstrating 12 months of sustained healthy behavior change for Dario members taking a GLP-1. - Announced new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR) demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.
- Announced two new studies published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine (JMIR), including a Randomized Controlled Trial (RCT) demonstrating the impact of a digital stress reduction program for teens.
Second Quarter 2024 Results Summary
Revenues for the second quarter ended June 30, 2024, were
B2B2C, employers and health plans recurring revenues for the second quarter ended June 30, 2024, were
Gross profit for the second quarter ended June 30, 2024, was
Pro-forma gross profit, excluding
Total operating expenses for the second quarter ended June 30, 2024, were
Total operating expenses excluding stock-based compensation, acquisition related expenses and depreciation for the second quarter of 2024 were
Operating loss for the second quarter of 2024 was
Financing income was
Net loss was
Net loss excluding stock-based compensation, acquisition related expenses and depreciation for the second quarter of 2024 was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Financial Results for the Six Months Ended June 30, 2024:
Revenues for the six months ended June 30, 2024, were
Gross profit for the six months ended June 30, 2024, was
Pro-forma gross profit, excluding
Total operating expenses for the six months ended June 30, 2024, were
Operating loss for the six months ended June 30, 2024, increased by
Financing income was
Net loss was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details: Thursday, August 8, 8:30am ET
Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)
Call me™: https://emportal.ink/3V5ogDP
Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to scheduled start time.
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1672806&tp_key=f245af335e
Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through Sunday, September 8th, 2024. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1163410.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, when the Company discusses its expected reduced operating expenses expected by Q1 2025 and the resulting operating losses by such time period, that it expects to reach breakeven by the end of 2025, its expected breakeven timeline is supported by its progress in its high margin B2B2C channel, its expected ARR in its B2B2C channel, that client adoption of the Twill platform will help it towards it cross-selling efforts, that it anticipates a significant reduction in operating losses over the next three quarters driven by robust revenue growth and aggressive cost-cutting measures, that its cost cutting measures are expected to yield a
Non-GAAP Financial Measures
We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, deferred inventory, depreciation of fixed assets, earn-out remeasurement and acquisition related expenses and amortization. We believe these measures provide useful information to management and investors for analysis of our operating results.
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | |||||
INTERIM CONSOLIDATED BALANCE SHEETS | |||||
June 30, | December 31, | ||||
2024 | 2023 | ||||
Unaudited | |||||
ASSETS | |||||
CURRENT ASSETS: | |||||
Cash and cash equivalents | $ | 22,938 | $ | 36,797 | |
Short-term restricted bank deposits | 859 | 292 | |||
Trade receivables, net | 6,731 | 3,155 | |||
Inventories | 5,133 | 5,062 | |||
Other accounts receivable and prepaid expenses | 3,679 | 2,024 | |||
Total current assets | 39,340 | 47,330 | |||
NON-CURRENT ASSETS: | |||||
Deposits | 6 | 6 | |||
Operating lease right of use assets | 1,547 | 967 | |||
Long-term assets | 134 | 143 | |||
Property and equipment, net | 1,334 | 899 | |||
Intangible assets, net | 22,346 | 5,404 | |||
Goodwill | 57,427 | 41,640 | |||
Total non-current assets | 82,794 | 49,059 | |||
Total assets | $ | 122,134 | $ | 96,389 | |
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||
INTERIM CONSOLIDATED BALANCE SHEETS | ||||
June 30, | December 31, | |||
2024 | 2023 | |||
Unaudited | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||
CURRENT LIABILITIES: | ||||
Trade payables | $ | 3,351 | $ | 1,131 |
Deferred revenues | 1,515 | 997 | ||
Operating lease liabilities | 884 | 111 | ||
Other accounts payable and accrued expenses | 6,475 | 6,300 | ||
Current maturity of long-term loan | 5,191 | 3,954 | ||
Total current liabilities | 17,416 | 12,493 | ||
NON-CURRENT LIABILITIES | ||||
Operating lease liabilities | 1,118 | 885 | ||
Long-term loan | 23,440 | 24,591 | ||
Warrant liability | 12,054 | 240 | ||
Other long-term liabilities | 51 | 36 | ||
Total non-current liabilities | 36,663 | 25,752 | ||
STOCKHOLDERS' EQUITY | ||||
Common stock of outstanding: 30,024,275 and 27,191,849 shares on June 30, 2024 and December 31, 2023, respectively | 3 | 3 | ||
Preferred stock of 40,331 and 18,959 shares on June 30, 2024 and December 31, 2023, respectively | *) - | *) - | ||
Additional paid-in capital | 431,526 | 407,502 | ||
Accumulated deficit | (363,474) | (349,361) | ||
Total stockholders' equity | 68,055 | 58,144 | ||
Total liabilities and stockholders' equity | $ | 122,134 | $ | 96,389 |
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | |||||||||||
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | |||||||||||
Three months ended | Six months ended | ||||||||||
June 30, | June 30, | ||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||
Unaudited | Unaudited | ||||||||||
Revenues: | |||||||||||
Services | $ | 4,660 | $ | 4,149 | $ | 8,820 | $ | 9,406 | |||
Consumer hardware | 1,595 | 2,003 | 3,193 | 3,812 | |||||||
Total revenues | 6,255 | 6,152 | 12,013 | 13,218 | |||||||
Cost of revenues: | |||||||||||
Services | 960 | 1,625 | 1,925 | 3,102 | |||||||
Consumer hardware | 1,306 | 1,359 | 2,504 | 2,699 | |||||||
Amortization of acquired intangible assets | 1,233 | 1,094 | 2,396 | 2,175 | |||||||
Total cost of revenues | 3,499 | 4,078 | 6,825 | 7,976 | |||||||
Gross profit | 2,756 | 2,074 | 5,188 | 5,242 | |||||||
Operating expenses: | |||||||||||
Research and development | $ | 6,810 | $ | 5,222 | $ | 13,452 | $ | 10,387 | |||
Sales and marketing | 7,132 | 6,460 | 14,042 | 12,800 | |||||||
General and administrative | 5,005 | 4,412 | 11,740 | 8,483 | |||||||
Total operating expenses | 18,947 | 16,094 | 39,234 | 31,670 | |||||||
Operating loss | 16,191 | 14,020 | 34,046 | 26,428 | |||||||
Total financial expenses (income), net | (2,581) | 2,565 | (11,267) | 2,982 | |||||||
Loss before taxes | 13,610 | 16,585 | 22,779 | 29,410 | |||||||
Income Tax | — | — | 1,994 | — | |||||||
Net loss | $ | 13,610 | $ | 16,585 | $ | 20,785 | $ | 29,410 | |||
Other comprehensive loss: | |||||||||||
Deemed dividend (contribution) | $ | (8,706) | $ | 1,691 | $ | (6,672) | $ | 1,691 | |||
Net loss attributable to common shareholders | $ | 4,904 | $ | 18,276 | $ | 14,113 | $ | 31,101 | |||
Net loss per share: | |||||||||||
Basic and diluted loss per share of common stock | $ | 0.08 | $ | 0.58 | $ | 0.27 | $ | 1.03 | |||
Weighted average number of common stock used in computing basic and diluted net loss per share | 39,830,793 | 28,186,345 | 37,778,087 | 27,879,881 | |||||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | |||||
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||
Six months ended | |||||
June 30, | |||||
2024 | 2023 | ||||
Unaudited | |||||
Cash flows from operating activities: | |||||
Net loss | $ | (20,785) | $ | (29,410) | |
Adjustments required to reconcile net loss to net cash used in operating activities: | |||||
Stock-based compensation | 10,420 | 10,148 | |||
Depreciation and impairment | 648 | 191 | |||
Change in operating lease right of use assets | 425 | 135 | |||
Amortization of acquired intangible assets | 2,516 | 2,238 | |||
Decrease (increase) in trade receivables, net | (247) | 1,595 | |||
Increase in other accounts receivable, prepaid expense and long-term assets | (1,171) | (476) | |||
Decrease (increase) in inventories | (71) | 2,042 | |||
Decrease in trade payables | (190) | (871) | |||
Decrease in other accounts payable and accrued expenses | (3,034) | (865) | |||
Decrease in deferred revenues | (224) | (531) | |||
Change in operating lease liabilities | (417) | (90) | |||
Change in fair value of warrant liability | (12,643) | — | |||
Non-Cash financial expenses | 204 | 1,501 | |||
Other | 96 | — | |||
Net cash used in operating activities | (24,473) | (14,393) | |||
Cash flows from investing activities: | |||||
Purchase of property and equipment | (85) | (220) | |||
Purchase of short-term investments | — | (4,996) | |||
Proceeds from redemption of short-term investments | — | 5,033 | |||
Payments for business acquisitions, net of cash acquired | (8,796) | — | |||
Net cash used in investing activities | (8,881) | (183) | |||
Cash flows from financing activities: | |||||
Proceeds from issuance of common stock, net of issuance costs | - | 1,410 | |||
Proceeds from issuance of preferred stock, net of issuance costs | 20,206 | 14,868 | |||
Proceeds from borrowings on credit agreement | — | 29,604 | |||
Repayment of long-term loan | — | (27,833) | |||
Net cash provided by financing activities | 20,206 | 18,049 | |||
Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents | (13,148) | 3,473 | |||
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents | (48) | — | |||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 36,797 | 49,470 | |||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | $ | 23,601 | $ | 52,943 | |
Supplemental disclosure of cash flow information: | |||||
Cash paid during the period for interest on long-term loan | $ | 1,972 | $ | 2,044 | |
Non-cash activities: | |||||
Right-of-use assets obtained in exchange for lease liabilities | $ | 428 | $ | 14 | |
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Three months ended June 30, 2024 | ||||||||
GAAP | Stock-Based Compensation Expenses | Amortization of acquisition related expenses and depreciation of fixed assets | Non-GAAP | |||||
Cost of Revenues | $ | 3,499 | (5) | (1,248) | 2,246 | |||
Gross Profit | 2,756 | 5 | 1,248 | 4,009 | ||||
Research and development | 6,810 | (448) | (63) | 6,299 | ||||
Sales and Marketing | 7,132 | (1,650) | (94) | 5,388 | ||||
General and Administrative | 5,005 | (1,459) | (553) | 2,993 | ||||
Total Operating Expenses | 18,947 | (3,557) | (710) | 14,680 | ||||
Operating Loss | $ | (16,191) | 3,562 | 1,958 | (10,671) | |||
Financing expenses | (2,581) | - | - | (2,581) | ||||
Income Tax | - | - | ||||||
Net Loss | $ | (13,610) | 3,562 | 1,958 | (8,090) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | |||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | |||||||
Three months ended June 30, 2023 | |||||||
GAAP | Stock-Based Compensation Expenses | Amortization of acquisition related expenses and depreciation of fixed assets | Non-GAAP | ||||
Cost of Revenues | $ | 4,078 | (17) | (1,124) | 2,937 | ||
Gross Profit | 2,074 | 17 | 1,124 | 3,215 | |||
Research and development | 5,222 | (1,302) | (16) | 3,904 | |||
Sales and Marketing | 6,460 | (1,824) | (45) | 4,591 | |||
General and Administrative | 4,412 | (2,149) | (34) | 2,229 | |||
Total Operating Expenses | 16,094 | (5,275) | (95) | 10,724 | |||
Operating Loss | $ | (14,020) | 5,292 | 1,219 | (7,509) | ||
Financing expenses | 2,565 | - | - | 2,565 | |||
Income Tax | - | - | |||||
Net Loss | $ | (16,585) | 5,292 | 1,219 | (10,074) | ||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | |||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | |||||||
Six months ended June 30, 2024 | |||||||
GAAP | Stock-Based Compensation Expenses | Amortization of acquisition related expenses and depreciation of fixed assets | Non-GAAP | ||||
Cost of Revenues | $ | 6,825 | (12) | (2,425) | 4,388 | ||
Gross Profit | 5,188 | 12 | 2,425 | 7,625 | |||
Research and development | 13,452 | (1,563) | (124) | 11,765 | |||
Sales and Marketing | 14,042 | (3,406) | (170) | 10,466 | |||
General and Administrative | 11,740 | (5,439) | (1,158) | 5,143 | |||
Total Operating Expenses | 39,234 | (10,408) | (1,452) | 27,374 | |||
Operating Loss | $ | (34,046) | 10,420 | 3,877 | (19,749) | ||
Financing expenses | (11,267) | - | - | (11,267) | |||
Income Tax | (1,994) | (1,994) | |||||
Net Loss | $ | (20,785) | 10,420 | 3,877 | (6,488) | ||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | |||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | |||||||
Six months ended June 30, 2023 | |||||||
GAAP | Stock-Based Compensation Expenses | Amortization of acquisition related expenses and depreciation of fixed assets | Non-GAAP | ||||
Cost of Revenues | $ | 7,976 | (44) | (2,236) | 5,696 | ||
Gross Profit | 5,242 | 44 | 2,236 | 7,522 | |||
Research and development | 10,387 | (2,487) | (35) | 7,865 | |||
Sales and Marketing | 12,800 | (3,671) | (89) | 9,040 | |||
General and Administrative | 8,483 | (3,946) | (69) | 4,468 | |||
Total Operating Expenses | 31,670 | (10,104) | (193) | 21,373 | |||
Operating Loss | $ | (26,428) | 10,148 | 2,429 | (13,851) | ||
Financing expenses | 2,982 | - | - | 2,982 | |||
Income Tax | - | - | |||||
Net Loss | $ | (29,410) | 10,148 | 2,429 | (16,833) | ||
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
Mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Media Contact:
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dariohealth-reports-second-quarter-2024-financial-and-operating-results-302217738.html
SOURCE DarioHealth Corp.
FAQ
What was DarioHealth's (DRIO) revenue in Q2 2024?
How much did DarioHealth's (DRIO) B2B2C revenue grow in Q2 2024?
When does DarioHealth (DRIO) expect to reach cashflow breakeven?
How much cash did DarioHealth (DRIO) have at the end of Q2 2024?
